[Care pathway of patients with hepatocellular carcinoma in France: State of play in 2017].
| Autor: | Costentin C; AP-HP, hôpital Henri-Mondor, service d'hépatologie, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94000 Créteil, France. Electronic address: Charlotte.costentin@aphp.fr., Ganne-Carrié N; AP-HP, hôpital Jean-Verdier, service d'hépatologie, avenue du 14-Juillet, 93140 Bondy, France., Rousseau B; AP-HP, hôpital Henri-Mondor, institut Mondor de recherche biomédicale, service d'oncologie médicale, Inserm U955 Équipe 18, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94000 Créteil, France., Gérolami R; Hôpital de la Timone, service d'hepato-gastro-entérologie, 264, rue Saint-Pierre, 13385 Marseille, France., Barbare JC; CHU d'Amiens, délégation à la recherche clinique et à l'innovation, site sud, 80054 Amiens cedex 1, France. |
|---|---|
| Jazyk: | francouzština |
| Zdroj: | Bulletin du cancer [Bull Cancer] 2017 Sep; Vol. 104 (9), pp. 752-761. Date of Electronic Publication: 2017 Jul 24. |
| DOI: | 10.1016/j.bulcan.2017.06.008 |
| Abstrakt: | Hepatocellular carcinoma is a major public health problem with one of the highest overall mortality compared to other cancers. The median overall survival in France in a hospital population with hepatocellular carcinoma is 9.4 months. Several publications reported a positive impact of hepatocellular carcinoma screening on diagnosis at an early-stage, eligibility for curative treatment and overall survival. However, the identification of patients to be included in a hepatocellular carcinoma screening program and the application of screening recommendations are not optimal. Other studies suggest a potentially negative impact of delayed diagnosis or treatment initiation on the patient's prognosis. Finally, marked variations between French regions and departments have been described in terms of access to curative treatment and overall survival. In this review article, we propose a state of play of the hepatocellular carcinoma patient's care pathway in France with the aim of identifying potential breaking points with negative impact on prognosis and of developing proposals for improvement. (Copyright © 2017 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|